Skip to main content

Table 1 Description of the cohorts

From: An isoform of AIF1 involved in breast cancer

Variables

Cohort 1 N = 13

Cohort 2 N = 74

Agea (years)

48.3 ± 9.3

51.9 ± 8.5

BMIa (kg/m2)

28.2 ± 6.8

26.2 ± 5.6

Menopausal statusb

 Premenopause

8 (61.54)

17 (22.97)

 Postmenopause

5 (38.46)

57 (77.03)

ER statusb

 Positive

8 (61.54)

69 (93.24)

 Negative

5 (38.46)

5 (6.76)

PR statusb

 Positive

7 (53.85)

65 (87.84)

 Negative

6 (46.15)

9 (12.16)

HER2 statusb

 Positive

4 (30.77)

8 (10.81)

 Negative

5 (38.46)

54 (72.97)

 Not assessable

4 (30.77)

12 (16.22)

BCb

 DCIS

4 (30.77)

5 (6.76)

 IDC

  Luminal

4 (30.77)

65 (87.84)

  HER2+

2 (15.38)

1 (1.35)

  Triple negative

3 (23.08)

1 (1.35)

  Unclassified

–

2 (2.70)

  1. BMI body mass index, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, BC breast cancer, DCIS ductal carcinoma in situ, IDC invasive ductal carcinoma
  2. Data presented as amean ± SD, bnumber of individuals (%)